Compare Moderna, Inc. (MRNA) vs Stitch Fix Inc (SFIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Stitch Fix Inc — how do they compare? Moderna, Inc. trades at $136.69 (market cap $54.14B), while Stitch Fix Inc trades at $2.9 (market cap $385.60M). The key difference: Moderna, Inc. is far larger — about 140.4× Stitch Fix Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Stitch Fix Inc nearer its low. Which is the better fit depends on your goals.
| MRNA | SFIX | |
|---|---|---|
Market Cap | $54.14B | $385.60M |
Sector | Health | Consumer Cyclical |
52-Week High | $174.38 | $5.80 |
52-Week Low | $22.36 | $2.89 |
Enterprise Value | $50.29B | $273.32M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
Stitch Fix (SFIX) trades at $2.97, down 2.62% on the day, reflecting ongoing investor caution despite recent operational improvements. The stock is technically bearish with key moving averages signaling selling pressure, while fundamentals show a narrowing net loss margin to -2.27% in 2025 from -9.64% in 2024, alongside a low price-to-sales ratio of 0.3. Recent news highlights AI-driven personalization efforts and exclusive brand collaborations aimed at boosting client engagement and revenue per user.
The outlook remains mixed; cost controls and revenue stabilization offer a path to profitability, but persistent net losses and competitive pressures pose risks. Analyst sentiment is cautious with a 63.64% hold rating, suggesting investors await clearer signs of a sustained turnaround before committing capital.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Stitch Fix Inc
Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →
